Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Urology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Bladder Carcinoma Clinical Trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (268) clinical trials

Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage

assess diagnostic performance of 3-Tesla DW-MRI in detecting and staging bladder cancer and potential role of the ADC value as a biomarker reflecting histological grade and stage.

Phase N/A

Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction

The registry includes patients after robot-assisted cystectomy, mainly as therapy for muscle invasive urothelial carcinoma. The urinary diversion will be completed intracorporeal either as ileal conduit or ileal neobladder. Outcome parameters include perioperative complications, oncologic data and oncologic follow-up data (tumor classification, recurrence, survival) as well as data on functional ...

Phase N/A

Application-based Perioperative Management of the Radical Cystectomy Patient

The purpose of this study is to learn whether it is feasible to use the LifeScience Technologies application (LST app) in patients undergoing radical cystectomy with the eventual goal to reduce complications and readmissions to the hospital after surgery.

Phase N/A

Molecular Biosensors for Detection of Bladder Cancer

The focus of this research is to discover urinary biomarker(s) that is distinct to bladder cancer, while developing molecular sensors that can detect the urinary anomalies. By applying in vitro selection techniques, both entities (biomarker discovery and sensor development) will be done simultaneously. All patients with bladder cancer diagnosis undergoing ...

Phase N/A

Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy

Aims and Objectives. The proposed research aims: firstly, to enhance our understanding of patient concerns, lifestyles, and values, that influence their choice of bladder reconstruction and predict their treatment satisfaction and quality of life (QoL); and, secondly, to initiate the development a novel decision-aid tool to help bladder-cancer patients, their ...

Phase N/A

The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence

Approximately 20% to 50% of patients with upper urinary tract urothelial carcinoma (UUT-UC) experience bladder recurrence after nephroureterectomy. Although many agents have been administered for the prevention of bladder recurrence, the standard prophylactic treatment has yet to be established. A meta-analysis found that a single instillation of chemotherapy immediately after ...


Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

To establish significant correlations between genetic polymorphisms and cancer, a largescale, systematic comparison of genetic alterations utilizing a case-control methodology is proposed. To date, such studies have been limited due to the large number of samples necessary for obtaining statistical significance, and the lack of rapid and accurate methods to ...

Phase N/A

Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy

Radical cystectomy (RC) represents the gold standard treatment for invasive bladder cancer. Reductions in morbidity and mortality from this operation have occurred in recent years through refined anaesthesia, surgical techniques, and centralization of services in high volume centres. The multimodal concept of enhanced recovery after RC (ERAS), which includes pre, ...

Phase N/A

Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer

Radical cystectomy remains the gold standard treatment for invasive non metastatic transitional cell cancer (TCC) of the bladder. In contemporary series, specific survival rates are about 60 to 65% at 5 years, decreasing for locally advanced disease to 45-50% in patients with nonorgan-confined lymph-node negative tumours and to 30-35% in ...


Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"

Very recently, pioglitazone was banned for use in type 2 diabetes patients in India as well, by the notification from Government of India based on a case series - the ban was revoked a few days later due to lack of evidence. The incidence rates of bladder cancer among different ...

Phase N/A